Matthew Monberg PhD

Matthew Monberg PhD

Adjunct Assistant Professor

Education

Ph.D., Epidemiology, University of Illinois at Chicago

M.S., University of the Sciences in Philadelphia

B.S., University of Notre Dame

Selected Scholarly Activity

Choy H, Gerber DE, Bradley JD, Iyengar P, Monberg MJ, Treat J, Govindan R, Koustensis A, Barker S, Obasaju C. Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: a systematic review of completed and ongoing studies. Lung Cancer. 2015; 87(3):232-240.

Arondekar B, Curkendall S, Monberg MJ, Mirakhur B, Oglesby A, Lenjart G, Meyer N. Economic burden associated with adverse events in patients with metastatic melanoma. Am J Managed Care. 2015; 21(2):158-164.

Treat J, Scagliotti GV, Peng G, Monberg MJ, Obasaju CK, Socinski MA. Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): a combined analysis of three phase 3 trials. Lung Cancer. 2012; 76(2):222-227.

Ortuzar W, Hanna N, Pennella E, Peng G, Langer C, Monberg MJ, Scagliotti G. Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small cell lung cancer. Clin Lung Cancer. 2012; 13(1):24-30.

Ansari RH, Socinski MA, Edelman MJ, Belani CP, Gonin R, Catalano RB, Marinucci DM, Comis RL, Obasaju CK, Chen R, Monberg MJ, Treat J. A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. Crit Rev Oncol Hematol. 2011; 78:162-171.

Zinner RG, Saxman SB, Peng G, Monberg MJ, Ortuzar WI. Treatment rationale and study design for a randomized trial of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small-cell lung cancer of nonsquamous histology. Clin Lung Cancer. 2010;11(5):352-357.

Treat J, Edelman MJ, Belani CP, Socinski MA, Monberg MJ, Chen R, Obasaju CK. A retrospective analysis of outcomes across histological subgroups in a three arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.  Lung Cancer. 2010; 70(3):340-346.

Movsas B, Langer CJ, Ross HJ, Wang L, Jotte RM, Feigenberg S, Xu F, Huang CH, Monberg MJ, Obasaju CK. Randomized phase II trial of cisplatin, etoposide and radiation followed by gemcitabine and docetaxel in stage II A/B unresectable non-small cell lung cancer. J Thorac Oncol. 2010; 5:673-679.

Reynolds C, Obasaju C, Schell MJ, Li X, Zheng Z, Boulware D, Caton JR, DeMarco LC, O’Rourke MA, Wright GS, Boehm KA, Asmar L, Bromund J, Peng G, Monberg MJ, Bepler G. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small cell lung cancer. J Clin Oncol. 2009; 27(34):5808-5815.

1Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, Flores R, Friedberg JS, Pisters K, Monberg MJ, Obasaju CK, Vogelzang NJ. Multicenter phase 2 trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27(18):3007-3013.

Gralla RJ, Edelman MJ, Detterbeck FC, Jahan TM, Loesch DM, Limentani SA, Govindan R, Peng G, Monberg MJ, Obasaju CK, Socinski MA. Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS). Support Care Cancer. 2009; 17(3):307-313.

Kulkarni PM, Chen R, Anand T, Monberg MJ, Obasaju CK. Efficacy and safety of pemetrexed in elderly cancer patients: results of an integrated analysis. Crit Rev Oncol Hematol. 2008; 67(1): 64-70.

Jänne PA, George R. Simon GR, Langer CJ, Taub RN, Dowlati A, Fidias P, Monberg MJ, Obasaju CK, Kindler H. Phase II Trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma. J Clin Oncol. 2008; 26: 1465–1471.

Professional Information

Director, Outcomes Research,
Merck and Company

Contact Information

Office location: Merck Research Laboratories
Mailing address: 351 N Sumneytown Pike, 2C011
North Wales, PA 19454
Office Phone: 267-305-0401
Email:

m [dot] monber [at] usciences [dot] edu